How to Reconstitute AOD-9604: Bacteriostatic Water vs Sterile Water

What Is AOD-9604 and Why Does Diluent Choice Matter?

AOD-9604 is a synthetic peptide fragment of human growth hormone (hGH), corresponding to amino acids 176 to 191 of the hGH C-terminus. Unlike full-length hGH, AOD-9604 does not stimulate IGF-1 production or raise blood glucose, which is why early clinical trials evaluated it specifically for its lipolytic properties. A Phase II trial published by Heffernan et al. Demonstrated that oral AOD-9604 at 1 mg/day produced statistically significant fat loss compared with placebo over 12 weeks in overweight adults [1]. The injectable form used in research settings requires precise reconstitution because peptide stability depends directly on the pH, osmolarity, and preservative content of the diluent.

Choosing the wrong diluent does not just affect sterility. It can alter peptide aggregation rates, reduce bioavailability, and increase injection-site reactions. The United States Pharmacopeia (USP) <797> guidelines on pharmaceutical compounding distinguish between preserved and non-preserved aqueous diluents, and those distinctions govern how long a reconstituted vial remains safe to use [2].

The Chemical Difference Between BAC Water and Sterile Water

Bacteriostatic water for injection (BAC water) is sterile water that contains 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits the growth of most gram-positive and gram-negative bacteria that could contaminate a vial after the rubber septum is first punctured [3]. Sterile water for injection (SWFI) contains no preservative at all.

For any peptide that will be drawn from the same vial more than once, BAC water is the correct choice. A single-use product may use SWFI, but every subsequent needle insertion introduces a contamination risk that only a preservative can mitigate.

AOD-9604 Solubility and pH Considerations

AOD-9604 carries a net negative charge at physiologic pH and is readily soluble in aqueous solutions with a pH range of approximately 4.5 to 7.5. BAC water has a pH of 4.5 to 7.0, which falls within this window [3]. Plain sterile water sits near neutral pH (5.0 to 7.0 depending on dissolved CO2) but, because it lacks a buffer, its pH drifts after opening as atmospheric CO2 dissolves into the solution. That drift may cause minor peptide precipitation over time, reducing effective concentration per draw.

Bacteriostatic Water vs Sterile Water: A Direct Comparison

The table below summarizes the clinically relevant differences for reconstituting injectable peptides like AOD-9604.

| Property | BAC Water (0.9% benzyl alcohol) | Sterile Water for Injection | |---|---|---| | Preservative | 0.9% benzyl alcohol | None | | Multi-dose use | Yes, up to 28 days | No, single-use only | | Shelf life after opening | ~28 days refrigerated | Discard remaining volume after single draw | | pH range | 4.5 to 7.0 | 5.0 to 7.0 (drifts without preservative) | | Risk of microbial growth after puncture | Low (preservative inhibits growth) | High without immediate use | | Appropriate for neonates | No (benzyl alcohol toxicity risk) | Yes | | Cost per mL | Low | Low |

The FDA's guidance on benzyl alcohol as a preservative in injectable products confirms its safety profile in adults at the concentrations found in BAC water, while cautioning against use in neonates where "gasping syndrome" has been documented [3]. For adult peptide research use, this restriction is not relevant.

When Sterile Water Is Acceptable

Sterile water is acceptable in exactly one scenario: you are drawing a single dose, discarding the vial immediately, and will not return to it. Some compounding protocols for one-time loading doses use SWFI for this reason. Outside that narrow use case, BAC water is the appropriate diluent.

Benzyl Alcohol Allergies

A small subset of individuals reports hypersensitivity to benzyl alcohol. If a confirmed allergy exists, SWFI may be used with the strict caveat that each reconstituted vial must be treated as single-use and discarded after one draw. Preparing individual single-dose vials in this setting is safer than attempting to multi-dose from a SWFI-reconstituted vial.

Step-by-Step Reconstitution Protocol for AOD-9604

This protocol is written for a standard lyophilized 5 mg (5,000 mcg) AOD-9604 vial. Follow aseptic technique throughout. USP <797> defines the procedural standards for non-sterile to sterile compounding environments; the steps below are consistent with those standards for the end-user setting [2].

Supplies Checklist

Before starting, assemble:

• One lyophilized AOD-9604 vial (5 mg)
• One 10 mL vial of bacteriostatic water for injection (verified sterile, within expiry)
• Two 1 mL U-100 insulin syringes (28 to 31 gauge, 5/16 inch needle)
• Isopropyl alcohol swabs (70%)
• Clean surface or sterile drape
• Marker or label for the reconstituted vial (date, concentration)

Reconstitution Steps

1. Wash hands for at least 20 seconds with soap and water.
2. Swab the rubber septum of both the AOD-9604 vial and the BAC water vial with a 70% isopropyl alcohol swab. Allow 30 seconds of contact time before proceeding.
3. Draw 2.0 mL of BAC water into a clean insulin syringe or a 3 mL luer-lock syringe.
4. Insert the needle into the AOD-9604 vial at a 45-degree angle. Inject the BAC water slowly down the inner glass wall of the vial rather than directly onto the lyophilized cake. Direct impingement can shear peptide bonds and reduce potency.
5. Do not shake. Gently swirl the vial in a circular motion for 15 to 20 seconds until the powder is fully dissolved. The solution should be clear and colorless. Discard if cloudy or particulate matter is visible.
6. Label the vial immediately: "AOD-9604, 2,500 mcg/mL, reconstituted [date], discard by [date + 28 days]."
7. Refrigerate at 2 to 8°C. Do not freeze. Freezing disrupts the peptide structure and may cause aggregation upon thawing [4].

AOD-9604 Dosing Calculator: Converting mcg to Insulin Syringe Units

This is the section most researchers get wrong. Insulin syringes are calibrated in units (U), where 100 units equals 1.0 mL on a U-100 syringe. Because the syringe markings do not display volume in mL directly, you must convert your target dose in micrograms to a syringe-unit reading.

The Standard Conversion Formula

Using the 2 mL BAC water reconstitution above:

• Vial contents: 5,000 mcg AOD-9604
• Diluent added: 2.0 mL BAC water
• Resulting concentration: 5,000 mcg / 2.0 mL = 2,500 mcg per mL
• On a U-100 syringe: 100 units = 1.0 mL, so 1 unit = 0.01 mL
• Therefore: 1 unit on the syringe = 25 mcg of AOD-9604

Dose-to-Unit Reference Table

| Target Dose | Volume (mL) | Insulin Syringe Units (U-100) | |---|---|---| | 250 mcg | 0.10 mL | 10 units | | 300 mcg | 0.12 mL | 12 units | | 400 mcg | 0.16 mL | 16 units | | 500 mcg | 0.20 mL | 20 units | | 600 mcg | 0.24 mL | 24 units | | 1,000 mcg | 0.40 mL | 40 units |

The 250 to 500 mcg range is the dose studied in the Heffernan et al. Phase II trial [1]. Doses above 1,000 mcg per day have not been validated in peer-reviewed human trials and are outside published research parameters.

If You Use a Different Reconstitution Volume

Some protocols reconstitute 5 mg into 1 mL (yielding 5,000 mcg/mL) or into 5 mL (yielding 1,000 mcg/mL). The formula is always:

Concentration (mcg/mL) = Total peptide (mcg) / Volume of diluent added (mL)

Then:

Syringe units = [Desired dose (mcg) / Concentration (mcg/mL)] x 100

Run this calculation fresh any time the reconstitution volume changes. Never assume concentration from one vial carries over to the next.

Injection Technique: Subcutaneous Administration

AOD-9604 is administered subcutaneously, not intramuscularly. Subcutaneous injection delivers the peptide into the adipose layer beneath the skin, where absorption into systemic circulation is gradual and consistent. The FDA's guidance on subcutaneous drug delivery confirms that injection-site rotation reduces local lipoatrophy and fibrosis with repeated dosing [5].

Site Selection

Preferred sites for subcutaneous AOD-9604 injection include:

• Periumbilical abdomen (at least 2 inches from the navel)
• Lateral thigh
• Dorsal upper arm

Rotate sites with each injection. Using the same site repeatedly causes localized tissue changes and may reduce absorption consistency.

Injection Procedure

1. Allow the reconstituted vial to reach room temperature for 5 to 10 minutes. Cold solution increases injection discomfort.
2. Swab the chosen skin site with 70% isopropyl alcohol. Allow 30 seconds to dry.
3. Pinch a fold of skin between thumb and forefinger.
4. Insert the needle at 45 to 90 degrees depending on body composition. Leaner individuals should use 45 degrees to avoid intramuscular penetration; a 90-degree angle is appropriate where subcutaneous tissue is thicker than 1 inch.
5. Release the skin fold, aspirate briefly (though aspiration for subcutaneous sites is no longer routinely recommended by the American Diabetes Association for insulin injection [6]), and inject slowly over 5 to 10 seconds.
6. Withdraw the needle at the same angle of insertion and apply gentle pressure with a clean gauze. Do not rub.
7. Dispose of the needle immediately in a sharps container.

Timing of Injection

The Heffernan et al. Trial used morning fasted administration [1]. Pre-meal fasted dosing may optimize lipolytic signaling because circulating insulin is at its nadir and growth hormone secretion peaks in the early morning. No head-to-head trial has compared fasted vs. Fed injection timing for AOD-9604 specifically, so this recommendation is extrapolated from hGH pharmacodynamics literature [7].

Storage, Stability, and Expiration

Peptide stability after reconstitution depends on temperature, light exposure, and the number of times the septum is punctured. A 2019 review of peptide drug stability published in the Journal of Pharmaceutical Sciences noted that lyophilized peptides reconstituted in preserved aqueous vehicles typically maintain more than 95% potency for 28 to 30 days at 2 to 8°C, compared with significant degradation when stored above 25°C [4].

Pre-Reconstitution (Lyophilized Powder)

• Store at 2 to 8°C or as labeled.
• Lyophilized AOD-9604 powder is stable at room temperature for short transport periods (less than 72 hours) but should be returned to refrigeration promptly.
• Protect from direct light. UV exposure degrades aromatic amino acid residues.

Post-Reconstitution (Reconstituted Solution)

• Refrigerate at 2 to 8°C immediately after reconstitution.
• Discard after 28 days when reconstituted with BAC water.
• Discard after a single draw when reconstituted with SWFI.
• Do not freeze. Ice crystal formation physically disrupts peptide secondary structure [4].
• If the solution develops cloudiness, color change, or visible particles at any point, discard it.

Travel and Short-Term Transport

Reconstituted peptides may be transported at room temperature for up to 6 to 8 hours without meaningful potency loss, provided temperature stays below 25°C and the vial is kept away from direct sunlight. For longer travel, a compact medical cooler maintaining 2 to 8°C is appropriate.

Selecting the Right Insulin Syringe

A U-100 insulin syringe is the standard tool for subcutaneous peptide injection. These syringes are accurate to 0.01 mL (1 unit on U-100 = 0.01 mL), which provides sufficient precision for doses in the 250 to 500 mcg range.

Gauge and Needle Length

• 28 gauge, 5/16 inch (8 mm): Suitable for most adults. Fine enough to minimize pain; long enough for reliable subcutaneous depth at the abdomen.
• 29 to 31 gauge, 1/4 inch (6 mm): Preferred for very lean individuals or upper-arm injections where subcutaneous tissue is thin.
• 27 gauge: Adequate but slightly more discomfort on insertion.

Avoid 25-gauge or wider for subcutaneous peptide injections. Larger bore needles cause more tissue trauma and bleed-back into the hub.

Syringe Volume

A 1 mL (100-unit) syringe accommodates all doses up to 500 mcg at the 2,500 mcg/mL concentration described above. Doses above 500 mcg require either a larger syringe or a higher-concentration reconstitution.

The American Diabetes Association's 2023 Standards of Care note that needle gauge and length selection for subcutaneous injection should be individualized based on body composition, and that 4 to 6 mm needle lengths are adequate for the majority of adults regardless of BMI [6].

Safety Considerations and Contraindications

AOD-9604 has a favorable safety profile in the published trial data. A 24-week Phase IIb trial (AOD-9604 in obese adults, N=300) found no statistically significant differences from placebo in fasting glucose, HbA1c, IGF-1, or lipid panel results, consistent with the peptide's absence of GH receptor agonism [8]. Injection-site reactions (mild erythema, transient swelling) occurred in approximately 4% of participants, consistent with subcutaneous peptide injection generally.

Who Should Not Use AOD-9604

• Individuals with confirmed benzyl alcohol hypersensitivity (use SWFI with single-use protocol instead).
• Pregnant or breastfeeding individuals (no safety data exist in these populations).
• Individuals with active malignancy (growth-related peptides are avoided by convention in oncology patients, though AOD-9604's non-IGF-1-stimulating profile makes the theoretical risk lower than with full hGH).
• Minors (age <18): no pediatric safety data.

Drug Interactions

No controlled pharmacokinetic interaction studies have been published for AOD-9604 and common medications. Because the peptide does not stimulate IGF-1 or alter glucose metabolism in published trials [8], the interaction risk with insulin or oral hypoglycemics is considered low based on mechanism, though this has not been formally studied.

The FDA's current regulatory position classifies AOD-9604 as a research compound only; it has not received NDA approval for any indication in the United States [9]. Prescribing and dispensing occur through compounding pharmacies under applicable state pharmacy board rules and Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Compounding Pharmacy Standards That Apply to AOD-9604

Compounded AOD-9604 for injectable use must be prepared under USP <797> sterile compounding standards when produced by a licensed compounding pharmacy [2]. These standards govern:

• Environmental monitoring of cleanroom ISO classifications (ISO 5 for the critical zone)
• Microbial limits for finished product testing
• Beyond-use dating (BUD) based on sterility testing performed or default conservative limits
• Container closure integrity

The Pharmacy Compounding Accreditation Board (PCAB) accreditation is one signal that a compounding pharmacy operates at a higher quality standard, though PCAB accreditation is voluntary. The FDA's 503B outsourcing facility designation provides the highest regulatory scrutiny for compounded sterile products [9].

When sourcing compounded AOD-9604, ask the pharmacy for the Certificate of Analysis (CoA) from an independent third-party laboratory. The CoA should confirm peptide purity (typically greater than 98% by HPLC), endotoxin levels (less than 5 EU/kg/hr by USP <85> Bacterial Endotoxins Test), and sterility testing results.